DNA Ligase I Inhibitors

The class of DNA Ligase I inhibitors encompasses a diverse range of chemical compounds that indirectly affect the function of DNA Ligase I by targeting various aspects of DNA replication and repair processes. These inhibitors do not directly target DNA Ligase I; instead, they modulate cellular processes that are prerequisites for or are related to the enzyme's activity. The primary mode of action for these inhibitors involves disrupting the normal progression of DNA replication or repair, thereby creating conditions where the function of DNA Ligase I is indirectly inhibited or becomes less efficient. Compounds such as Hydroxyurea and Aphidicolin interfere with the precursor stages of DNA synthesis, affecting the availability of substrates necessary for DNA Ligase I activity. DNA-interacting agents like Camptothecin, Etoposide, and Doxorubicin create additional challenges for DNA repair mechanisms, indirectly increasing the stress on DNA Ligase I function. Nucleoside analogs such as Gemcitabine and antimetabolites like 5-Fluorouracil disrupt the incorporation of nucleotides during DNA synthesis, potentially hindering the ligation process. Other compounds, including Cisplatin and Mitomycin C, induce DNA damage that can complicate the replication process, indirectly affecting DNA Ligase I's role in DNA repair. Additionally, inhibitors of DNA damage response proteins like Olaparib (PARP inhibitor) and AZD6738 (ATR inhibitor) can influence the broader context in which DNA Ligase I operates, affecting its role in DNA repair and replication.